REMARKS

Claims 1-10 have been canceled, and claims 11-27 have been added. Thus, claims 11-27 are pending.

Added claims 11-27 are supported by the originally filed application. Claim 1, for example, is supported in the specification at page 2, lines 3-6, and page 6, lines 7-18. No new matter is added.

Please charge any requisite fee to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,

PAUL D. GOLIAN
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 42,591
TELEPHONE: (302) 992-3749
FACSIMILE: (302) 892-1026

Dated: _2/20/02_

VERSION WITH MARKING TO SHOW CHANGES MADE

In showing the changes, deleted material is shown in brackets, and inserted material is shown underlined.

IN THE SPECIFICATION:

Paragraph beginning at page 1, line 3:

This application <u>is a divisional of U.S. Application No. 09/371,056 filed August 9, 1999, whose contents are incorporated by reference, and</u> claims the benefit of U.S. Provisional Application No. 60/096,342, filed August 12, 1998.

Paragraph beginning at page 7, line 4:

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without [effecting] <u>affecting</u> the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

IN THE CLAIMS:

Claims 1-10 canceled.

Claims 11-27 added.